| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.27) per share. This is a 62.5 percent increase over losses...
 
																	Upgrades
 
																	Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
 
																	
 
																	According to data from Benzinga Pro, during Q2, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $33.31 million...
 
																	Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.
 
																	HC Wainwright & Co. analyst Oren Livnat downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
 
																	Gainers